<?xml version="1.0" encoding="UTF-8"?>
<ref id="B79">
 <label>79.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Zhang</surname>
    <given-names>C</given-names>
   </name>
   <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml">, </span>
   <name name-style="western">
    <surname>Wu</surname>
    <given-names>Z</given-names>
   </name>
   <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml">, </span>
   <name name-style="western">
    <surname>Li</surname>
    <given-names>JW</given-names>
   </name>
   <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml">, </span>
   <name name-style="western">
    <surname>Zhao</surname>
    <given-names>H</given-names>
   </name>
   <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml">, </span>
   <name name-style="western">
    <surname>Wang</surname>
    <given-names>GQ</given-names>
   </name>
  </person-group>
  <article-title>The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality</article-title>. 
  <source>Int. J. Antimicrob. Agents.</source> (
  <year>2020</year>) (
  <comment>Epub ahead of print</comment>).
 </mixed-citation>
</ref>
